Wikipedia
Zicronapine
Zicronapine (, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.
Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D, D and serotonin 5HT receptors.
In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising medicine Lu AF35700.